Marinomed Biotech AG Logo

Marinomed Biotech AG

Develops virus-blocking products & immunology therapies via proprietary technology platforms.

MARI | VI

Overview

Corporate Details

ISIN(s):
ATMARINOMED6
LEI:
529900GN3B1EN80XF405
Country:
Austria
Address:
Hovengasse 25, 2100 Korneuburg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marinomed Biotech AG is a science-based biopharmaceutical company that develops innovative therapies for diseases in virology and immunology. The company leverages two proprietary technology platforms: Carragelose®, a virus-blocking compound used in globally marketed nasal sprays and lozenges, and Marinosolv®, a technology platform that enhances the solubility of poorly soluble compounds to develop new treatments for various immunological conditions. Marinomed's business model encompasses in-house development of medicinal products and medical devices, as well as strategic partnerships to commercialize its pipeline and technologies. The company focuses on addressing conditions with limited or no effective treatment options, particularly in respiratory and autoreactive immune disorders.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 10:01
Declaration of Voting Results & Voting Rights Announcements
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 Börs…
English 16.5 KB
2025-10-31 10:01
Declaration of Voting Results & Voting Rights Announcements
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 13…
German 17.0 KB
2025-10-31 10:00
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 135, Section 1 BorseG with the objective of Europe…
English 3.6 KB
2025-10-06 14:58
Regulatory News Service
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Mari…
English 34.6 KB
2025-10-06 14:58
M&A Activity
EQS-Adhoc: Marinomed Biotech AG startet Prüfung strategischer Optionen für die …
German 36.4 KB
2025-10-06 14:56
Regulatory News Service
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv plat…
English 11.1 KB
2025-09-17 13:48
Earnings Release
Marinomed Biotech AG announces results for the first half year of 2025
English 10.6 KB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
English 3.4 MB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines F…
German 3.5 MB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory s…
English 31.7 KB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG beschließt Kapitalerhöhung unter Bezugsrechtsau…
German 33.7 KB
2025-09-16 15:22
Share Issue/Capital Change
Marinomed Biotech AG resolves capital increase excluding statutory subscription…
English 8.0 KB
2025-09-02 09:18
Pre-Annual General Meeting Information
EQS-AGM: Marinomed Biotech AG: Convening of an Extraordinary General Meeting fo…
English 51.6 KB
2025-09-02 09:17
Pre-Annual General Meeting Information
EQS-HV: Marinomed Biotech AG: Einberufung einer außerordentlichen Hauptversamml…
German 50.1 KB
2025-09-02 09:16
Pre-Annual General Meeting Information
Marinomed Biotech AG: Convening of an Extraordinary General Meeting for Tuesday…
English 21.9 KB

Automate Your Workflow. Get a real-time feed of all Marinomed Biotech AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marinomed Biotech AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Marinomed Biotech AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain GRF
Grifols SA Logo
Develops plasma-derived medicines and transfusion solutions for rare and chronic conditions.
United States of America GRFS
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia GRD1R
GSK plc Logo
Develops specialty medicines and vaccines to prevent and treat a range of global diseases.
United States of America GSK
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea 036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America GYRE
Haleon plc Logo
A consumer healthcare leader offering trusted OTC brands for everyday health and wellness.
United States of America HLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.